Evidence map›Paper›PMID 33928818›Full record

ArticleTechnology in cancer research & treatment

Prognostic Role of RASSF1A, SOX17 and Wif-1 Promoter Methylation Status in Cell-Free DNA of Advanced Gastric Cancer Patients.

Evangelos I Karamitrousis, Ioanna Balgkouranidou, Nikolaos Xenidis, Kyriakos Amarantidis, Eirini Biziota, Triantafyllia Koukaki, Grigorios Trypsianis, Anastasios Karayiannakis, Helen Bolanaki, George Kolios and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Kinetic Profiling ofJCO precision oncology · 2024
    Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Evangelos I KaramitrousisDepartment of Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.ORCID 0000-0002-9110-6104
Ioanna BalgkouranidouDepartment of Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Nikolaos XenidisDepartment of Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Kyriakos AmarantidisDepartment of Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Eirini BiziotaDepartment of Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Triantafyllia KoukakiDepartment of Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Grigorios TrypsianisDepartment of Medical Statistics, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Anastasios KarayiannakisSecond Department of Surgery, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Helen BolanakiSecond Department of Surgery, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
George KoliosLaboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Evi LianidouDepartment of Chemistry, Analysis of Circulating Tumor Cells, Lab of Analytical Chemistry, University of Athens, Athens, Greece.
Stylianos KakolyrisDepartment of Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
Democritus University of Thrace · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic modification of several genes is a key component in the development of gastric cancer. The methylation status of

Indexed as

DNA MethylationPromoter Regions, GeneticAdaptor Proteins, Signal TransducingBiomarkers, TumorCell-Free Nucleic AcidsDNA, NeoplasmFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisSOXF Transcription FactorsStomach NeoplasmsSurvival RateAdaptor Proteins, Signal TransducingBiomarkers, TumorCell-Free Nucleic AcidsDNA, NeoplasmRASSF1 protein, humanSOX17 protein, humanSOXF Transcription FactorsTumor Suppressor ProteinsWIF1 protein, humangastric cancermethylationRASSF1ASOX17Wif-1

Identifiers

PMID33928818
PMCPMC8113658
OpenAlexW3158082243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.